annual meeting program - American Society of Clinical Oncology

TUESDAY
Tuesday, June 8, 2010
9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION
Genitourinary (Testes, Kidney, and Bladder) Cancer
Location: E Arie Crown Theater
CME credit: 3
Track(s): Genitourinary Cancer
Deborah Ann Bradley, MD—Co-Chair
Duke University Medical Center
Hyung Lae Kim, MD—Co-Chair
Roswell Park Cancer Institute
9:30 AM A randomized phase III study comparing standard-dose BEP with sequential
high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem cell support in
males with poor prognosis germ cell cancer (GCC): An intergroup study of
EORTC, GTCSG, and Grupo Germinal (EORTC 30974). (Abstract #4512)
G. Daugaard, I. A. Skoneczna, N. Aass, R. De Wit, M. De Santis, H. Dumez,
S. Marreaud, L. Collette, C. Bokemeyer, H. Schmoll
9:45 AM Conventional-dose versus high-dose chemotherapy in relapsed or refractory
male germ-cell tumors: A retrospective study in 1,594 patients. (Abstract
#4513)
A. Lorch, C. Mollevi, A. Kramar, L. H. Einhorn, A. Necchi, C. Massard, U. DeGiorgi,
A. Flechon, K. A. Margolin, J. Beyer, for the International Prognostic Factors
Study Group
Discussion
10:00 AM Derek Raghavan, MD, PhD (Abstracts #4512–4513)
Cleveland Clinic
Treatment Intensity and Outcome in Germ Cell Tumors
10:15 AM The high-dose aldesleukin (HD IL-2) SELECT trial in patients with metastatic
renal cell carcinoma (mRCC). (Abstract #4514)
D. F. McDermott, M. S. Ghebremichael, S. Signoretti, K. A. Margolin, J. Clark,
J. A. Sosman, J. P. Dutcher, T. Logan, R. A. Figlin, M. B. Atkins, Cytokine
Working Group
10:30 AM A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in
patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine
Working Group Study (CWGS). (Abstract #4530)
U. B. Dandamudi, M. S. Ghebremichael, J. A. Sosman, M. M. Regan, M. B. Atkins,
J. Clark, J. P. Dutcher, B. D. Curti, U. N. Vaishampayan, M. S. Ernstoff, Cytokine
Working Group
10:45 AM Can the combination of temsirolimus and bevacizumab improve the
treatment of metastatic renal cell carcinoma (mRCC)? Results of the
randomized TORAVA phase II trial. (Abstract #4516)
B. J. Escudier, S. Negrier, G. Gravis, C. Chevreau, R. Delva, J. Bay, L. Geoffrois,
E. Legouffe, E. Blanc, C. Ferlay
Discussion
11:00 AM Dror Michaelson, MD, PhD (Abstracts #4514, 4530, and 4516)
Massachusetts General Hospital
Metastatic Renal Cell Carcinoma: Which Way Forward?
11:15 AM Results of a phase III randomized trial of synchronous chemoradiotherapy
(CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder
cancer (MIBC) (BC2001 CRUK/01/004). (Abstract #4517)
N. D. James, S. A. Hussain, E. Hall, P. Jenkins, J. Tremlett, C. Rawlings,
C. Hendron, R. Lewis, S. Rogers, R. A. Huddart, on behalf of the BC2001
Investigators
438